Antimalarial drug discovery: Efficacy models for compound screening

Fidock, DA; Rosenthal, PJ; Croft, SL; Brun, R; Nwaka, S; (2004) Antimalarial drug discovery: Efficacy models for compound screening. Nature reviews Drug discovery, 3 (6). p. 509. ISSN 1474-1776 DOI:

Full text not available from this repository.


Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of compounds for development, yet little attempt has been made to review and standardize antimalarial drug-efficacy screens. Here, we suggest different in vitro and in vivo screens for antimalarial drug discovery and recommend a streamlined process for evaluating new compounds on the path from drug discovery to development.

Item Type: Article
Keywords: Plasmodium-falciparum malaria, rodent malaria, chloroquine, resistance, in-vitro, protein farnesyltransferase, sulfadoxine-, pyrimethamine, uncomplicated malaria, cysteine protease, toxoplasma-gondii, randomized trial, Animals, Antimalarials, chemistry, therapeutic use, Drug Evaluation, methods, Drug Resistance, physiology, Human, Malaria, drug therapy, epidemiology, Models, Biological, Technology, Pharmaceutical, methods
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Malaria Centre
PubMed ID: 15173840
Web of Science ID: 222187600020


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item